Adapted from Bonow et al. (383). JACC Vol. 62, No. 16, 2013 Yancy et al. October 15, 2013:1495 539 2013 ACCF/AHA Heart Failure Guidelines: Executive Summary other comorbidities from enrollment, thus limiting our ability to generalize our recommendations to many real-world patients. Therefore, the clinician must, as always, practice the art of using the best of the guideline recommendations as they apply to a speci c patient. Future research will need to focus on novel pharmacolog- ical therapies, especially for patients hospitalized with HF; regenerative cell-based therapies to restore myocardium; and new device platforms that will either improve existing tech- nologies (e.g., CRT, ICD, left ventricular assist device) or introduce simpler, less morbid devices that are capable of changing the natural history of HF. What is critically needed is an evidence base that clearly identi es best processes of care, especially in the transition from hospital to home. Finally, preventing the burden of this disease through more successful risk modi cation, sophisticated screening, perhaps using speci c omics technologies (i.e., systems biology), or effective treatment interventions that reduce the progression from stage A to stage B is an urgent need. 